Search PubMed⌕ Search

Biomedical subjects

F Pileggi

Publications and source records attributed to F Pileggi.

At least 253 records · Page 14Linked to original sources
PubMed1988

Infective endocarditis related to acute cholecystitis.

A 30-year-old woman with a homologous dura-mater valve prosthesis developed infective endocarditis related to acute purulent cholecystitis occurring in chronic cholelithiasis. During anti-bacterial treatment refractory heart failure ensued which compelled replacement of the infected prosthesis. She died in the post-operative period. Autopsy revealed endocarditis on the implanted bioprosthesis, purulent cholecystitis and a gallbladder stone. It is warningly concluded that the surgical treatment of endocarditis was unsuccessful because of persistence of purulent cholecystitis that led to reinfection of the inserted prosthesis.

Acute Disease↗
PubMed1988

Campylobacter fetus endocarditis on a prosthetic heart valve.

Campylobacter fetus infection in man is rare. Few cases of Campylobacter endocarditis have been described, and none have been associated with a prosthetic heart valve. We have reported a case of Campylobacter fetus ssp fetus on a prosthetic mitral valve in a 48-year-old woman who was treated successfully with penicillin and streptomycin (and later with gentamicin). Replacement of the prosthetic valve was done because of stenosis and vegetations. Pathologic examination showed vegetations on a calcified prosthesis, but no bacteria were seen.

Campylobacter Infections↗
PubMed1988

Difference between the response of the pulmonary and systemic circulation during exercise in congestive heart failure.

Thirty nine patients with cardiomyopathy were evaluated by a hemodynamic study at rest and during isotonic exercise. These patients were divided into two groups on the basis of their left ventricular ejection fraction (LVEF): A, control group (LVEF greater than 40%, N = 19); B, severe congestive heart failure group (LVEF less than or equal to 40%, N = 20). Patients in group A showed adequate cardiovascular responses to exercise, i.e. increased cardiac index (80%) and stroke volume index (17%), decreased systemic vascular resistance (36.8%) but no significant change in pulmonary arteriolar resistance values. In contrast, patients in group B showed a slight and heart rate-dependent increase in cardiac index (38.5%), no improvement of stroke volume index (-3.4%), decreased systemic vascular resistance (21.6%) and increased pulmonary arteriolar resistance (41.2%) with exercise. This group also showed a significant increase in right atrial pressure that might reflect a decrease in right ventricular performance secondary to an abnormal pulmonary vascular response during exercise.

Adult↗
PubMed1988

Ventricular fibrillation in acute experimental myocardial ischemia: protection by magnesium sulfate.

1. The efficacy of magnesium sulfate for prevention of ventricular fibrillation was compared with that of the calcium blocker verapamil and other antiarrhythmic drugs in 54 open-chested anesthetized dogs during a 3-h ligation of the circumflex coronary artery. Latency time to fibrillation, incidence of fibrillation and hemodynamic parameters were assessed. 2. Ventricular fibrillation occurred in 11 of 14 (79%) control dogs, in 2 of 8 (25%) dogs treated with magnesium sulfate (100 mg/kg) and in none of 8 animals treated with verapamil (0.2 mg/kg) (P = 0.014 and P = 0.0004, respectively, in comparison with controls); lidocaine (60 mg followed by 4 mg/min), amiodarone (5 mg/kg) and propafenone (4 mg/kg) had no effect on the incidence of fibrillation. 3. The latency time to fibrillation was 11.6 +/- 9.1 min in controls and it was shortened to 4.0 +/- 3.8 min (P = 0.039) in dogs treated with propafenone, but was unaffected by other drugs. 4. There was no correlation between pre-occlusion heart rate or blood pressure and fibrillation incidence. 5. In this experimental model, magnesium sulfate infusion had a protective effect against ventricular fibrillation that was similar to verapamil, suggesting that magnesium sulfate may be useful as an antifibrillatory agent during acute ischemia.

Analysis of Variance↗